Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q1 2024 · 10-Q
Revenue—
Net Income-$8.67M-$8.67MN/M vs Q1 2023 EPS Diluted-$0.31-$0.31N/M vs Q1 2023 Operating Income-$9,597,000N/M Operating Cash Flow-$7,374,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
Free Cash Flowderived-$7,385,000N/M ended Mar 31, 2024 · filed Apr 26, 2024 · 26 d after period end